CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2011	Dec. 31, 2010
Revenues:
Research and development support	$ 945	$ 2,005	$ 2,013	$ 3,500
License and milestone fees	6,025	866	7,212	2,676
Clinical materials reimbursement	647	1,307	928	1,413
Total revenues	7,617	4,178	10,153	7,589
Operating Expenses:
Research and development	15,559	16,004	32,720	29,429
General and administrative	4,834	3,688	9,675	7,052
Total operating expenses	20,393	19,692	42,395	36,481
Loss from operations	(12,776)	(15,514)	(32,242)	(28,892)
Other income, net	23	1,281	6	1,771
Loss before provision for income taxes	(12,753)	(14,233)	(32,236)	(27,121)
Provision for income taxes	0		0
Net loss	$ (12,753)	$ (14,233)	$ (32,236)	$ (27,121)
Basic and diluted net loss per common share (in dollars per share)	$ (0.17)	$ (0.21)	$ (0.42)	$ (0.40)
Basic weighted average common shares outstanding (in shares)	76,523	67,965	76,443	67,961
Diluted weighted average common shares outstanding (in shares)	76,523	67,965	76,443	67,961